Overview
of Clinical Responsibilities
The
clinical services are consultative in nature providing formal
and informal consultation to the psychiatric staff including psychiatrist
attendings and residents. This includes monitoring and adjusting
of medications, education, referrals, and treatment planning.
He provides direct consultation for Tuesday afternoons (Dr. Klamen
and Dr. Doves) clinics and Thursday morning clinic with Dr. Krasuski.
Provide psychopharmacology lectures during the supervision rounds,
provide assessment of extra-pyramidal side effects (EPS) utilizing
the AIMS or Discus rating scales. Provide written psychopharmacology
recommendations to the attending psychiatrist. He is also available
for additional consultative support to the psychiatrist including:
Computer searches of past hospitalizations, medications and laboratory
reports if indicated by the patient. A copy of the data will be
included in the patient’s records to be reviewed by the psychiatrist.
Obtain a base-line blood pressure, heart rate, and body weight
when appropriate. Administer haloperidol or fluphenazine decanoate
IM injections when treatment is ordered. Also, he can be called
to administer and assess clinical rating instruments such as the
Beck’s Depression Inventory or Geriatrics Depression Scale and
provide a basic neuro-psychiatric mental status testing. In addition,
he can provide Clozapine monitoring services: Benefits of service
include: - 1) The availability of consultative support in initiating
clozapine and monitoring patients (i.e. WBC, Abnormal Involuntary
Movements, Drug interactions, Adverse side-effects). 2) Developing
guidelines for the prescribing and monitoring of Clozapine in
the ambulatory setting.
He
also an investigator and research coordinator for out-patient
studies (see below). The responsibilities are to assist and supervise
subject recruitment and consent to participate in research, management
of the study records, storage, accountability, and dispensing
of study medications, and tracking subject study timetables. He
also provides clinical monitoring of patients in the clinical
studies. Has received training at UIC to administer the following
clinical rating scales: Mongomery Asbury Depression Scale, Hamiltion
Depression Rating Scale and the Brief Psychiatric Rating Scales.
He
provides services to the Partial Hospital Program which includes
a pharmacist facilitated medication education group once a week
and weekly staff meetings. The Medication Education Group is a
unique learning environment for pharmacy and medical students
on psychiatry rotation. Patients included in the group are patients
who are clinically stable on current medication prescribed by
the attending psychiatrist. The attending psychiatrist will be
notified if the patient’s symptoms are acute and require further
interventions beyond the services of the Medication Education
Group. The education groups discuss a wide variety of topics including
common medication side-effects, common psychiatric symptoms, compliance
issues, drug and food interactions, time to treatment response,
and duration of treatment. Patients are introduced to the staff
and each other prior to starting the group. If some patients are
new to the group the facilitator will usually ask for a volunteer
from the group to explain the purpose of the group. The facilitator
will facilitate group discussion about medications. To facilitate
discussion, the facilitator may review an individual patient’s
medications, determine if other patients are on similar medications
and then facilitate a discussion focused on the medication class
and characteristics common with the medications. The group forum
allows the pharmacist to assess the patients may require the pharmacist
to contact the attending psychiatrist to discuss problems and
recommendations to the attending psychiatrist. Then the pharmacist
documents and discusses pertinent information with the attending
psychiatrist.
Provides
psychopharmacological education to the pharmacy, medical, nursing,
social work, and psychology trainees and staff.
Specialty
Certification
|
DATE
1997 – 2001
|
CERTIFICATE
Board Certified Psychiatric
Pharmacist (BCPP)
|
Professional
Education
|
DATE
|
INSTITUTION
|
DEGREE
|
|
1990 – 1992
|
University of Kentucky, College
of Pharmacy, Lexington, Kentucky
|
Doctor of Pharmacy
|
|
1981 – 1986
|
Ferris State University,
College of Pharmacy, Big Rapids, Michigan
|
Bachelor of Science in Pharmacy
|
Post-Doctoral Training
|
DATE
|
INSTITUTION
|
CERTIFICATE
|
|
1993 – 1994
|
Western Missouri Mental Health
Center
Kansas City, Missouri
|
Fellowship in Psychiatric
Pharmacotherapy
|
|
1992 – 1993
|
Western Missouri Mental Health
Center Kansas City, Missouri
|
ASHP Accredited Residency
in Psychiatric Pharmacotherapy
|
Academic
Appointments
|
DATE
|
INSTITUTION
|
POSITION
|
|
1995 – Present
|
University of Illinois at
Chicago Chicago, Illinois
|
Assistant Clinical Professor,
Calendar year appointment
|
|
1994 - 1995
|
University of Kentucky Lexington,
Kentucky
|
Assistant Clinical Professor,
Calendar year appointment
|
|
1992 - 1994
|
University of Missouri-Kansas
City Kansas City, Missouri
|
Clinical Instructor
|
Hospital
Appointments
|
DATE
|
INSTITUTION
|
POSITION
|
|
1999 – Present
|
University of Illinois Medical
Center Department of Pharmacy Practice Chicago, Illinois
|
Pharmacotherapist in Ambulatory
Care Psychiatry
|
|
1995 - 1999
|
Michael Reese Hospital and
Medical Center Departments of Pharmacy and Psychiatry
Chicago, Illinois
|
Pharmacotherapist in Psychiatry
|
|
1994 - 1995
|
Appalachian Regional Healthcare
Psychiatric Center, Hazard, Kentucky
|
Psychopharmacy Specialist
|
|
1992 – 1994
|
Veterans Administration,
Kansas City, Missouri
|
I.V. Pharmacist, part-time
|
|
1991 – 1992
|
Good Samaritan Hospital,
Lexington, Kentucky
|
Staff Pharmacist, part-time
|
|
1986 – 1990
|
United States Public Health
Service (USPHS) Indian Health Service (IHS) Chinle, Arizona
|
Senior Assistant Pharmacist;
Temporary Chief Pharmacist, Kayenta, Arizona.
|
Honors
- The
Rho Chi Honor Society, April 12th, 2000
- Scholarship
Award, Bristol-Myers Squibb U.S. Pharmaceutical Division,
1993
- Promotion,
Lieutenant, E-3, Senior Assistant Pharmacist, 1989
- USPHS
Isolative Hardship Award, 1987
Professional
Activity
- Member,
American Society of Health-System Pharmacists 1986 - 2000
- Member,
American Pharmaceutical Association 1986 - 2000
- Member,
Illinois Chapter of the Society of Health-System Pharmacists
1997 - 2000
Publications:
Under
Peer-review:
- Schneiderhan,
ME, Kaplan KJ. Autonomy, Gender and Preference for Paternalistic
or Informative Physicians: A Study of the Doctor-Patient Relations.
JAMA, 2000 (submitted).
- Kaplan
KJ, Harrow M, Schneiderhan ME. Patient Gender, Doctor Involvement,
and decisions on Dying. Lancet, 2000 (submitted).
Peer-reviewed
Published:
- Schneiderhan
ME. Physician-Assisted Suicide and Euthanasia: The Pharmacist’s
Perspective. In: Kaplan KJ. ed. Right to Die versus Sacredness
of Life. Baywood Publishing Co. Inc. Amityville, NY. and
Omega, 2000;40(1):89-99.
- Kaplan
KJ, Lachenmeier F, Harrow M, O’Dell J, Uziel O, Schneiderhan
ME, Cheyfitz K. Psychosocial versus Biomedical Risk Factors
in Kevorkian’s first 47 Physician-Assisted Deaths. In: Kaplan
KJ. ed. Right to Die versus Sacredness of Life. Baywood
Publishing Co. Inc. Amityville, NY. and Omega, 2000;40(1):109-163.
- Marken
PA, Schneiderhan ME. Assessment of Psychiatric Illness. In:
DiPiro, Talbert, Hayes, Yee, Matzke, Posey. eds. Pharmacotherapy:
A Pathophysiological Approach, Fourth Edition. 1999;58:1039-1055.
- Bunker
MT, Marken PA, Schneiderhan ME, Ruehter VL. Attenuation of
antipsychotic-induced hyperprolactinemia with clozapine. J
Child Adolesc Psychopharmacol 1997;7(1):65-69.
- Littrell
RA, Schneiderhan M, The Neurobiology of Schizophrenia. Pharmacotherapy
1996;16(6):143s-147s; discussion 166s-168s.
- Marken
PA, Schneiderhan ME. Assessment of Psychiatric Illness. In:
DiPiro, Talbert, Hayes, Yee, Matzke, Posey. eds. Pharmacotherapy:
A Pathophysiological Approach, Third Edition. 1996;61:1293-1300.
- Schneiderhan
ME, Marken PA. An atypical course of neuroleptic malignant
syndrome. J Clin Pharmacol. 1994;34(4):325-334.
- Schneiderhan
ME. Is vitamin E effective in the treatment of tardive dyskinesia.
Ann Pharmacother. 1993;27(3):311-312.
Peer-reviewed:
In Preparation:
- Schneiderhan
ME. Refining Practice with Outcomes Data. Unit 4. UK Prime
Care Disease State Management Module. University of Kentucky
Office of Continuing Pharmacy Education, 2000.
- Schneiderhan
ME, Littrell RA. The Pharmacist’s Role in Caring for the Patient
with Depression. Unit 3. UK Prime Care Disease State Management
Module. University of Kentucky Office of Continuing Pharmacy
Education, 2000.
- Marken
PA, Schneiderhan ME. Assessment of Psychiatric Illness. In:
DiPiro, Talbert, Hayes, Yee, Matzke, Posey. eds. Pharmacotherapy:
A Pathophysiological Approach, Fifth Edition. 2000.
Letter:
- Schneiderhan
ME, Gross AG, Marken PA; Ruehter VL, Schmidt SL. Conversion
from oral to i.m. fluphenazine not a simple matter. Am
J Health Syst Pharm 1995 Dec 15:52(24):2826-7.
Abstracts:
- Kaplan
KJ, Harrow M, Schneiderhan ME. Patient Gender, Doctor Involvement,
and Decisions on Dying. The One Hundered and Fifty-Third Annual
Meeting of the American Psychiatric Association. May 13-18th.
2000;15C:62.
- Schneiderhan
ME, Gross AC, Kendall MM, Schmidt SL, Renno VL, Marken PA.
A Drug Utilization Evaluation of Fluphenazine Decanoate Conversion
in a State Psychiatric Hospital. ASHP Midyear Clinical Meeting
29:P-456(E) (Dec) 1994. (IPA #3111872)
- Jaggers
M, Schneiderhan M, et al. Absence of antimicrobial resistance
with restricted use of nalidixic acid for shigellosis. USPHS
Professional Association, Abstract, 25th Annual Meeting, June
3 - 6, 1990.
Research
Projects
Funded
Grants/Sponsorships:
-
Clinician-Patient
Relationship Preferences Among Male and Female Psychiatric
Patients. Sponsored by Research Infrastructure Support Program
(RISP), Co-investigator Awarded $8000.00.
-
The
Assessment of Nizatidine for the Prevention of Olanzapine-Associated
weight gain in patients with Schzophrenia. Sponsored by Lilly
Research. Co-coordinator, April, 2000. IRB approved
-
A
Development Model of Doctor-Patient Relations. Kaplan K.,
Schneiderhan ME. The 1999 Summer Student Research Fellowship
Program. Sponsored by the Research and Education Foundation
of the Michael Reese Medical Staff. $1,800; June 1999.
-
A
Development Model of Doctor-Patient Relations. Kaplan K.,
Schneiderhan ME. The 1998 Summer Student Research Fellowship
Program. Sponsored by the Research and Education Foundation
of the Michael Reese Medical Staff. $1,800; June 1998.
-
A
Development Model of Doctor-Patient Relations. Kaplan K.,
Schneiderhan ME. The 1997 Summer Student Research Fellowship
Program. Sponsored by the Research and Education Foundation
of the Michael Reese Medical Staff. $1,800; June 1997.
-
A
Retrospective Comparison of Valproic Acid and Lithium in Patients
with Manic Symptoms. Abbott Pharmaceuticals Inc. Approved
and funded; $5000; September, 1993.
-
Fluphenazine
Decanoate Drug Use Evaluation. UpJohn. Approved and funded;
$1000; October, 1993.
Unfunded
Grants:
-
A
Randomized, Blinded, Comparison of Clinical and Economic outcomes
in a Bipolar Disorder Critical Pathway Model Versus a Traditional
Clinical Model. Seabolt J., Schneiderhan, ME. Submitted to
Abbott Laboratories; March 16, 1998.
-
A
Randomized, Blinded, Comparison of Clinical and Economic outcomes
in a Major Depression Critical Pathway Model Versus a Traditional
Clinical Model. Seabolt J., Schneiderhan, ME. Submitted to
1998 NARSAD Young Investigator Award and HansVahlteich Endowment
Program Funds.
-
Pharmacist
Perspective of Physician Assisted Death in Michigan, Illinois,
and Oregon: An Empirical Study. Schneiderhan ME. 1998 HansVahlteich
Endowment Program Funds.
-
A
Comparison of Antidepressant Treatment Outcome and Utilization
of Psychiatric Services in HIV-infected Patients versus Non-HIV-Infected
Patients with Major Depression. Submitted to the Michael Reese
Research Foundation.
Speaking
Engagements
- Kaplan
KJ, Harrow M, Schneiderhan ME. "Patient Gender, Doctor
Involvement, and Decisions on Dying." Symposium 15: Doctor
influence on Hastened Death in Women and Men Worldwide. The
One Hundered and Fifty-Third Annual Meeting of the American
Psychiatric Association. Chicago, May 15th. 2000.
- Schneiderhan
ME. "Pharmaceutical Care of the Adolescent Depressed
Patient." Presented at UIC sponsored Drug Management
of Childhood and Adolescent Depression and Suicide. Oak Brook,
April 7th, 2000.
©2001
Department of Psychiatry
UIC 912 S. Wood Street
Chicago , IL - 60612, USA
Phone: 1-312-996-7206
webmaster@psych.uic.edu
|